[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-abnormalities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-abnormalities":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,52,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100629279","obesity-medicine-bank-of-the-quebec-heart-and-lung-institute---laval-university-iucpq-ulaval-100629279",false,"NCT07472608","Obesity Medicine Bank of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)","Database and Biological Material Bank in Obesity Medicine of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)","To be included in the registry (database + biobank), a person must first be referred to the Bariatric Medicine Clinic at the IUCPQ-ULaval and meet several criteria:\n\n1. Be over 18 years of age\n2. Meet at least one of the following five criteria:\n\n   1. Body mass index ≥30 kg\u002Fm2 with or without comorbidities (preclinical or clinical obesity);\n   2. Require weight loss related to a transplant, bariatric surgery, or another type of surgery (e.g., hernia repair, orthopedic surgery, neurosurgery, etc.);\n   3. History of bariatric surgery resulting in weight regain of at least 15% of the total weight lost;\n   4. History of bariatric surgery resulting in weight loss deemed insufficient by the treating medical team;\n   5. Having undergone bariatric surgery with complications related to it (i.e., flushing syndrome or hypoglycemia, nephrolithiasis, return of comorbidities in remission, abnormalities in phosphocalcic balance and vitamin deficiencies).","ALL","18 Years",{"count":19,"type":20},25000,"ESTIMATED","25 Years","OBSERVATIONAL","Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Many diseases are associated with obesity, such as type 2 diabetes, hypertension, cardiovascular diseases, numerous cancers, gynecological disorders, etc. Focusing on obesity medicine is crucial for improving patients' quality of life, reducing healthcare costs, and developing effective prevention strategies. The Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) maintains a clinical database and biological material bank for studying the multidisciplinary management of obesity and its complications.\n\nA biobank is a collection of information, clinical or biochemical data (including radiological, cardiac, and genetic data), and blood samples concerning donors. The information that can be collected includes, for example, age, sex, diagnosis, progression or treatment of a medical condition, medications, DNA, etc. DNA is a molecule present in all cells and contains all the information necessary for the development and functioning of our body.\n\nThis bank aims to better characterize patients' profile receiving follow-up care in obesity medicine, identify predictive factors of success or failure of interventions and adapt management strategies according to specific needs. The collected data and blood samples will be used in several research projects with the following objectives:\n\n1. To document the socioeconomic, demographic, clinical, radiological, genetic, and biochemical characteristics of patients living with obesity and requiring medical follow-up at the bariatric medicine clinic at the IUCPQ-ULaval\n2. To explore the effects or associations of genetic and biochemical determinants on health in the context of obesity\n3. To gain a better understanding of the pathophysiology and genes involved in obesity and associated metabolic abnormalities\n4. To evaluate the clinical utility of non-invasive biomarkers in the screening of preclinical obesity and its comorbidities and\u002For\n5. To evaluate the effectiveness of medications, health behavior changes, and bariatric surgery in order to develop optimal interventions aimed at improving the health and medical management of people with obesity.",[25,26,27],"Obesity","Metabolic Abnormalities","Health",[29,30,31,32,33,34,35,36,37,27,38],"Biobank","Clinical data","Radiological data","Genetic data","Biochemical data","Cardiac data","Blood samples","Prospective patient registry","Bariatric medicine","Obesity medicine","NOT_YET_RECRUITING","2026-03-11",{"date":42,"type":43},"2026-03-16","ACTUAL",{"date":45,"type":20},"2026-06-01",{"date":47,"type":20},"2051-06",{"name":49,"class":50},"Institut universitaire de cardiologie et de pneumologie de Québec, University Laval","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":51},"100629138","frequency-of-mafld-and-its-association-with-nutritional-status-and-metabolic-risk-factors-in-a-rural-population-of-bangladesh-100629138","NCT07470749","Frequency of MAFLD and Its Association With Nutritional Status and Metabolic Risk Factors in a Rural Population of Bangladesh","Inclusion Criteria:\n\n* Age 18 years or above\n* Resident of the selected community\n\nExclusion Criteria:\n\n* Pregnant women\n* Severe illness precluding participation like paralysis, bed ridden, cancer etc",true,{"count":60,"type":20},1000,"Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly recognized cause of chronic liver disease and is closely linked with obesity, metabolic abnormalities, and nutritional status. Data on the frequency of MAFLD and its associated metabolic and nutritional factors in rural populations of Bangladesh are not up to date.\n\nThis study aims to determine the frequency of MAFLD and to evaluate its association with nutritional status and metabolic risk factors among adults in a rural population of Bangladesh. Eligible participants will undergo clinical assessment, anthropometric measurements, laboratory evaluation of metabolic parameters, and abdominal ultrasonography for the detection of hepatic steatosis. Nutritional status will be assessed using standard anthropometric and clinical criteria.\n\nThe findings of this study are expected to provide baseline epidemiological data on MAFLD in rural Bangladesh and to help identify associated metabolic and nutritional risk factors.",[63,26,64],"MAFLD","Obesity & Overweight","RECRUITING","2026-03-10",{"date":68,"type":43},"2026-03-13",{"date":70,"type":43},"2025-12-04",{"date":72,"type":20},"2026-10-31",{"name":74,"class":50},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":51},"100627197","high-phenolic-olive-oil-for-enhancing-metabolic-health-a-randomized-controlled-trial-in-patients-with-central-obesity-hope-100627197","NCT07445503","High Phenolic Olive Oil for Enhancing Metabolic Health: a Randomized-controlled Trial in Patients With cEntral Obesity (HOPE)","High Phenolic Olive Oil for Enhancing Metabolic Health: a Randomized-controlled Trial in Patients With Central Obesity","HOPE","Inclusion Criteria:\n\n* Adult men and women 18-80 years of age,\n* Overweight\u002Fobesity (body mass index \\> 25 or waist circumference \\>94 cm for males and \\>80 cm for females), and\n* The presence of at least one of the following metabolic abnormality: (1) triglyceride level ≥150 mg\u002FdL or HDL cholesterol ≤40 mg\u002FdL in men and ≤50 mg\u002FdL in women; (2) increased blood pressure ≥ 130\u002F85 mm Hg; (3) elevated fasting blood sugar ≥100 mg\u002FdL; (4) standardized drug treatment regimen, and\n* Provided signed informed consent for participation.\n\nExclusion Criteria:\n\n* Concomitant acute or chronic disease (e.g., infection, cancer, chronic heart failure, kidney disease, autoimmune diseases like rheumatoid arthritis, inflammatory bowel diseases, Hashimoto),\n* Untreated diabetes,\n* Women at pregnancy or lactation,\n* Individuals with psychiatric or mental disorder,\n* Any use of antioxidant-phytochemical rich supplement, anti-, pre- or probiotics pre-intervention,\n* Drug and\u002For alcohol abuse,\n* Those who did not consent or were unable to provide consent.","80 Years",{"count":85,"type":20},80,"INTERVENTIONAL",[88],"NA","Olive oil is a fundamental component of the Mediterranean diet and a major source of monounsaturated fatty acids with well-established cardioprotective properties. When rich in phenolic compounds-such as hydroxytyrosol, tyrosol, oleuropein, oleocanthal, oleacein, and ligstroside aglycone-it is considered a functional food with antioxidant, anti-inflammatory, cardioprotective, chemoprotective, and neuroprotective effects. According to EU Regulation 432\u002F2012, daily consumption of 20 g of extra virgin olive oil containing at least 5 mg of hydroxytyrosol and tyrosol derivatives (250 mg\u002Fkg) contributes to the protection of blood lipids from oxidative stress and qualifies for a health claim.\n\nOverweight\u002Fobesity, characterized by excessive fat accumulation, is strongly associated with non-communicable diseases, including cardiovascular disease, type 2 diabetes, hypertension, certain cancers, and neurodegenerative disorders. Chronic low-grade inflammation and oxidative stress are key mechanisms underlying obesity-related metabolic disorders. Although dietary energy restriction remains the primary approach for weight management, growing research interest focuses on natural products rich in phenolic compounds as potential modulators of molecular pathways involved in central obesity.\n\nHowever, robust clinical evidence in humans with central obesity and metabolic abnormalities remains limited. Therefore, this double-blind, randomized, controlled trial aims to investigate the effects of extra virgin, high-phenolic olive oil (HPOO) compared with low-phenolic olive oil (LPOO) in adults with overweight\u002Fobesity with metabolic abnormalities. Participants will consume the assigned olive oil type (HPOO or LPOO) for eight weeks.\n\nAt baseline and trial endpoint (8 weeks), data collection will include anthropometric measurements, dietary intake, biochemical indices, inflammatory and oxidative stress markers in blood samples, hormones, bioavailability of phenolic compounds, as well as lifestyle parameters i.e., health-related quality of life, physical activity levels, sleep quality. Ethical approval, informed consent, and data protection procedures will be strictly followed. Statistical analyses will be conducted using SPSS software (SPSS Inc, ΙΒΜ, Chicago, IL, USA).\n\nThe study is anticipated to explore whether consumption of high-phenolic olive oil favorably modulates markers related to obesity and metabolic abnormalities, while also improving nutritional status and quality-of-life parameters.",[91,92,26,93],"Adults","Overweight , Obesity","Consented to Participate in the Trial and Signed an ICF",[95,96,97,98,99,100,101],"extra virgin, high-phenolic olive oil","overweight","obesity","metabolic disorders","metabolism","oxidative stress","inflammation","2026-02-26",{"date":104,"type":43},"2026-03-03",{"date":106,"type":43},"2025-03-03",{"date":108,"type":20},"2027-05",{"name":110,"class":50},"University of Peloponnese"]